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New fourteen antimony(III) complexes of general formula [SbLnCl3] (where n= 1 or 2, L =2-aminopyridine, 5-methyl-2-
aminopyridine, 2-aminopyrimidine, 4,6-dimethoxy-2-aminopyrimidine, 2-benzyl-2-thiopseudeourea,2-guanidinobenzimidazole,  
2-amino-5-thiol-4,6-dimethoxypyrimidine, 2-amino-5-(1H-tetrazol-5-ylthio)-4,6-dimethoxypyrimidine, N-2-pyrimidine,
2-piperidinecarboxamide, N-2-pyrimidine, 2-pyrrolidinecarboxamide, 2-amino-5-(1H-tetrazol-5-iltiyo)-4,6-
dimethoxypyrimidine-2-pyrrolidinecarboxamide and N-2-pyrimidine, 5-chloro-2-thiophenecarboxamide, N-2-benzothiazol-
2-pyrrolidinecarboxaamide, N,N-(1,2-phenyl)dipyrrolidine-2-carboxamide) have been synthesized and their anti-leishmanial
activity have been assessed in vitro against Leishmania tropica promastigotes. The best complex, Sb(2-
guanidinobenzimidazole)Cl3 is demostrated 3.16% growth inhibition at a concentration of 31.25 μg/mL. In general,
antimony(III) complexes containing pyrimidine ligands has showed higher anti-leishmanial activity than antimony(III)
complexes bearing pyridine ligands, and electron-donating substituents decrease the anti-leishmanial activity. All complexes
have been optimised with DFT/B3LYP/LANL2DZ method in the gas phase. Several descriptors are tested to find a
quantitative correlation between anti-leishmanial activity and structural properties of the complexes by best multiple linear
regression method. Good correlations are obtained with minimum net atomic charge for a C atom and maximum bond order
of a Cl atom. The developed QSAR equation is internally validated.
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Leishmaniasis is a deadly disease caused by 
parasitic protozoa of the genus Leishmania. The fatal 
version of the disease, Visceral leishmaniasis, causes 
about 1.5–2 million new cases per year1. According to 
the World Health Organization (WHO), leishmaniasis 
is the second most important neglected tropical 
disease, and can have a fatality rate as high as 
100% within two years2. Despite the growing 
importance of this disease, very few studies have been 
carried out on the development of new antileishmanial 
drugs. In fact, antimony(IV) compounds, meglumine 
antimoniate (Glucantime) and sodium stibogluconate 
(Pentostam) have been used in the treatment of 
leishmaniasis for over 50 years, but clinical resistance 
to these drugs has emerged.3,4 Therefore, more efforts 
in leishmanial drug discovery are urgently needed 
todevelop cheap, safe and effective new drugs. 
Pentavalent antimonial are known to be prodrugs and 
they are reduced to active Sb(III) form inside the 
macrophage and parasite cell.5-7 Additionally, 
antimony complexes have various potential usage in 
the field of health and pharmacy8,9 such as 
anthelminthic,10,11 antitrypanosomal,12 antimicrobial13 
and anticancer14-17 as well as antileishmanial18-20 
agents. Furthermore, antimony compounds are used 
popularly as catalysts in organic synthesis.21-23 
Quantitative structure–activity relationship 
(QSAR) methods have been widely used for drug 
discovery, lead optimization and toxicity prediction 
vs. traditional QSAR studies pioneered by Hansch et al. 
is a useful approach to correlate the bioactivity of 
compounds with structural and physicochemical 
parameters.24,25 In the literature, anti-leishmanial 
activity of organic compounds and Bi, Fe, Mn like 
metal complexes have been previously reported.26-34 
However, no QSAR equation was reported for anti-
leishmanial activity of antimony(III) compounds. 
Recently, we synthesized and characterized 
new fourteen antimony(III) complexes, 
[Sb(2-aminopyridine)2Cl3] (1), [Sb(5-methyl-2-




aminopyridine)2Cl3] (2), [Sb(2-aminopyrimidine)2Cl3] 





Cl3] (8), [Sb(N-2-pyrimidine, 2-piperidinecarboxamide) 
Cl3] (9), [Sb(N-2-pyrimidine, 2-pyrrolidinecarboxamide) 






(14).35-37 In this study, all complexes were evaluated 
for their in vitro anti-leishmanial activity against 
promastigote forms of Leishmania tropica. All 
complexes were optimized at DFT/B3LYP/ 
LANL2DZ level in gas phase. Then, approximately 
370 molecular descriptors (constitutional, topological, 
geometrical, electrostatic, and quantum-chemical) of 
the complexes were calculated. A quantitative 
structure activity relationship (QSAR) study was 
carried out to get more insights into parameter 
responsible for the anti-leishmanial activity. 
 
Materials and Methods 
All chemicals were purchased from Sigma-Aldrich, 
and used without further purification. The NMR 
spectra were recorded in d6-DMSO in a Bruker Ultra 
shield 300 MHz spectrometer. Elemental analyses 
were determined on a LECO CHNS–932 auto 
elemental analysis apparatus. The molecular 
conductivities were measured with WTW Cond 330i. 
Infrared spectra were recorded using a Mattson 1000 
FTIR Spectrometer, from 4000–400 cm−1 in KBr 
pellet. Liquid Chromatography Mass spectra were 
obtained by using a Paltform LC-MS with methanol- 
acetonitrile mixture as the solvent. 
 
Synthesis and characterization of the complexes 
All complexes were synthesized as described  
in literatüre.35-37 Thus, methanolic solution of 
antimony(III) chloride was slowly added to methanolic 
solution of relate ligand in the mole ratio of 2:1 in 
hydrochloric acid, and the resulting solution was 
refluxed for 2 days at 60 °C. Then the mixture was 
concentrated to 1/3 of its initial volume and allowed to 
stand for crystallization at room temperature. 
[Sb(2-aminopyridine)2Cl3] (1): Anal. Calcd. for 
C10H12Cl3N4Sb: C, 28.85; H, 2.91; N, 13.46. Found: 
C, 28.17; H, 2.75; N, 13.97 IR (KBr, /cm−1): 3442  
( NH2), 1661( CC), 1621 ( CN), 994( CH).  
LC-MS (MeOH): m/z [found (calcd)]: 418.34 
(416.35) (M+2): 1H NMR (300 MHz, DMSO-d6): δ 
2.50 (2H, NH2), 7.95 (H1, Ar), 7.90 (H3, Ar), 6.98  
(H4, Ar), 6.86 (H3, Ar), m.p. 174-175 °C,  
yield: 58.82%.  
[Sb(5-methyl-2-aminopyridine)2Cl3] (2): Anal. 
Calcd. for C12H16Cl3N4Sb: C, 32.43; H, 3.63; N, 
12.61. Found: C, 33.02; H, 3.82; N, 12.10. IR  
(KBr, /cm−1): 3429 ( NH2), 3040 ( CH), 1668  
( CC), 1625 ( CN). LC-MS: m/z (calcd) = 444.40 
(444.86) (M+). 1H NMR (300 MHz, DMSO-d6): 
δ 2.2 (3H, CH3), 3.50 (2H, NH2), 6.95 (H6, Ar),  
7.8 (H5, Ar), 7.90 (H1, Ar), m.p. 174-176 °C,  
yield: 87.12 %. 
[Sb(2-aminopyrimidine)2Cl3] (3): Anal. Calcd. 
For C8H10Cl3N6Sb: C, 22.97; H, 2.41; N, 20.09. 
Found: C, 23.39; H, 2.71; N, 20.74. IR (KBr, /cm−1): 
3346 ( NH2), 1658 (CCring), 1619 (CNring), 990 
(CHring). LC-MS: m/z (calcd) = 420.32 (419.35) 
(M+1). 1H NMR (300 MHz, DMSO-d6): δ 5.40  
(2H, NH2), 8.40 (H1, H3, Ar), 6.75 (H2, Ar), m.p.  
170-171 °C, yield: 62.50 %.  
[Sb(4-6-dimethoxy-2-aminopyrimidine)2Cl3] (4): 
Anal. Calcd. for C14H20Cl3N4O4Sb: C, 26.77; H, 3.37; 
N, 15.61. Found: C, 27.11; H, 3.67; N, 15.96. IR 
(KBr, /cm−1): 3391 ( NH2), 2940 ( CH), 2909 ( 
CH), 1684 ( CC), 1656 ( CN), 939 ( CH). LC-MS: 
m/z (calcd) = 540.43 (539.15) (M+1). : 1H NMR  
(300 MHz, DMSO-d6): δ 3.50 (2H, NH2), 4.90 (3H, 
OCH3), 5.70 (1H, Ar), m.p. ˃ 400 °C, yield: 30.24 %.  
[Sb(2-benzyl-2-thiopseudeourea)2Cl3] (5): Anal. 
Calcd. for C16H18Cl3N4S2Sb: C, 34.40; H, 3.25; N, 
10.03; S, 11.48. Found: C, 34.77; H, 3.18; N, 10.43; 
S, 11.97. IR (KBr, /cm−1): 3305 ( NH2), 3194  
( NH), 3085 ( CH), 1637 (CCar), 1385 ( CH). 
LC-MS: m/z (calcd) = 560.59 (559.51) (M+1). 1H 
NMR (300 MHz, DMSO-d6): δ 4.50 (2H, CH2S), 7.40 
(5H, Ar), 9.30 (2H, NH2) and 9.10 (1H, NH), m.p. ˃ 
400 °C, yield: 54.27 %.  
[Sb(2-guanidinobenzimidazole)Cl3] (6): Anal. 
Calcd.for C8H9Cl3N5Sb: C, 23.82; H, 2.25; N, 17.36. 
Found: C, 23.37; H, 2.02; N 17.13. IR (KBr, /cm−1): 
3430 ( NH2), 3333 ( NH), 3063 ( CH), 1689  
( CC), 1629 ( CN). LC-MS: m/z (calcd) = 404.08 
(403.31) (M+1): 1H NMR (300 MHz, DMSO-d6): δ 
11.90 (1H, NH), 8.20 (1H, NH), 7.40 and 7.20  




(4H, Ar), 6.40 (3H, NH2 and NH), m.p. 217-218 °C, 
yield: 53.22 %.  
[Sb(2-amino-5-thiol-4,6-dimethoxypyrimidine)2Cl3] 
(7): Anal. Calcd.forC12H18Cl3N6O4S2Sb: C, 25.28; H, 
3.43; N, 13.61; S, 10.38. Found: C, 24.37; H, 3.74; N, 
13.82; S, 11.03. IR (KBr, /cm−1): 3466 ( NH2), 
2941 ( CH), 1653 ( CN). LC-MS: m/z (calcd) = 
603.09 (602.66) (M+1). 1H-NMR (300 MHz, DMSO-
d6): 10.65 (1H, SH), 7.00 (2H, NH2), 3.66 (6H, CH3). 
13C-NMR (100 MHz, DMSO-d6): 171.67, 170.44, 
163.47, 71.83, 55.27, m.p. ˃ 400 °C, yield: 35%. 
[Sb(2-amino-5-(1H-tetrazol-5-ylthio)-4,6-
dimethoxypyrimidine)2Cl3] (8): Anal. Calcd. for 
C14H18Cl3N14O4S2Sb:C, 22.77; H, 2.46; N, 26.55; S, 
8.68. Found: C, 23.07; H, 2.79; N, 26.11; S, 9.04. IR 
(KBr, /cm−1): 3431 ( NH2), 3332 ( NH), 2922 ( 
CH), 1701 ( CC), 1649 ( CN). LC-MS: m/z (calcd) 
= 779.03 (738.63) (M+ CH3CN). 
1H NMR (300 MHz, 
DMSO-d6): 15.60 (1H, NH), 7.20 (2H, NH2), 3.80 
(6H, CH3). 
13C-NMR (100 MHz, DMSO-d6): δ 
172.24, 171.11, 162.84, 156.33, 75.37, 54.92, m.p. ˃ 
400 °C, yield: 46%. 
[Sb(N-2-pyrimidine-2-piperidinecarboxamide)Cl3] 
(9): Anal. Calcd. forC10H14Cl3N4OSb: C, 27.65; H, 
3.25; N, 12.90. Found: C, 28.11; H, 3.44; N, 13.18. IR 
(KBr, /cm−1):3422 ( NH), 1662 ( CO), 1592  
( CN), 1109 ( CH). LC-MS: m/z (calcd) = 435.15 
(434.36) (M+1). 1H NMR (300 MHz, DMSO-d6): 
8.50 (1H, NH), 7.60 (2H, H), 6.80 (1H, H), 3.80 (1H, 
CH), 3.50 (2H, -CH2), 2.00 (2H, CH2) 2.90 (1H, -
NH), 1.75 (2H, -CH2), 1.60 (2H, -CH2). 
13C NMR 
(100 MHz, DMSO-d6): δ 171.03, 169.68, 158.86, 
157.98, 110.83, 58.55, 43.94, 28.05, 21.61, 19.01, 
m.p. ˃ 400 °C, yield: 84%. 
[Sb(N-2-pyrimidine-2-pyrolincarboxamide)Cl3] 
(10): Anal. Calcd. forC9H12Cl3N4OSb: C, 25.72; H, 
2.88; N, 13.33.Found: C, 25.19; H, 2.97; N, 13.21. IR 
(KBr, /cm−1):3368 ( NH), 1649 ( CO), 1637  
( CN), 987 ( CH). LC-MS: m/z (calcd) = 453.19 
(420.33) (M+CH3OH). 
1H NMR (300 MHz, DMSO-
d6): 9,40 (1H,-NH), 8,10 – 6.10 (3H, Har), 4,40 (1H, 
CH), 3.70 (2H, CH2), 3.30 (2H, CH2), 2.25 (1H, 
NH),1.90 (2H, -CH2). 
13C NMR (100 MHz, DMSO-
d6): δ 169.70, 164.64, 160.33, 158.15, 110.55, 59.09, 
46.08, 28.18, 23.56, m.p. ˃ 400 °C, yield: 43%. 
[Sb(2-amino-5-(1H-tetrazole-5-ylthio)-4,6-
dimethoxypyrimidine-2-pyrrolinecarboxamide)Cl3] 
(11): Anal. Calcd. forC12H16Cl3N8O3SSb:C, 24.83; H, 
2.78; N, 19.30; S, 5.52. Found: C, 24.12; H, 2.83; N, 
19.78; S, 5.76. IR (KBr, /cm−1):3462.90 ( NH), 
2955.31 ( NH), 1639.91 ( CO), 1547.55 ( CN), 
1450 ( CC). LC-MS: m/z (calcd) = 580.29 (580.48) 
(M+). 1H NMR (300 MHz, DMSO-d6): δ 15.80 (1H, 
NH), 11.02 (1H, NH), 4,20 (1H, CH), 4.00 (2H, CH2), 
3.70 (6H, OCH3), 1.95 (1H, NH). 
13C NMR  
(100 MHz, DMSO-d6): δ 175.63, 162.57, 162.53, 
50.48, 63.87, 45.55, 33.13, 28.34, m.p. ˃ 400 °C, 
yield: 35%. 
[Sb(5-chloro-N-(2-pyrimidine)-2-thiophencarboxa 
mide)2Cl3] (12): Anal. Calcd. for C18H12Cl5N6O2S2Sb: 
C, 30.56; H, 1.71; N, 11.88; S, 9.06. Found: C, 30.79; 
H, 1.87; N, 11.26; S, 8.89. IR (KBr, /cm−1): 
3373.90( NH), 1667.84 ( CO), 1627.92 ( CN), 
1536.33 ( CC). LC-MS: m/z (calcd) = 708.08 
(707.46) (M+1). 1H NMR (300 MHz, DMSO-d6): δ 
8.58 (1H, NH), 8.30 (1H, H), 7.60 (1H, H), 7.25 (1H, 
H), 6.80 (2H, H), 13C NMR (100 MHz, DMSO-d6): δ 
162.28, 157.67, 157.18, 135.29, 133.88, 133.83, 
128.11, 110.32, m.p. ˃ 400 °C, yield: 80%. 
[Sb(N-2-benzothiazole-2-pyrrolidinecarboxamide) 
Cl3] (13):Anal. Calcd. For C12H13Cl3N3OSSb: C, 
30.32; H, 2.76; N, 8.84; S, 6.74. Found: C, 30.26; H, 
2.68; N, 8.62; S, 6.47. IR (KBr, /cm−1): 3374 ( 
NH), 3114 ( NH), 1634 ( CO), 1572 ( CN). LC-
MS: m/z (calcd) = 476.17 (475.43) (M+1).1H NMR 
(300 MHz, DMSO-d6): 9.60 (1H, NH), 7.80 (1H, H), 
7.45 (1H, H), 7.35 (1H, H), 7.20 (1H, H), 4.40 (1H, 
CH), 3.75 (2H, CH2), 3.20 (2H, -CH2), 2.25 (1H, 
NH), 1.90 (2H, CH2). 
13C NMR (100 MHz, DMSO-
d6): δ 169.64, 168.66, 143.32, 127.34, 126.44, 
123.69, 122.91, 115.70, 59.20, 45.89, 28.15, 23.54, 
m.p. ˃ 400 °C, yield: 78%. 
[Sb(N,N-(1,2-phenyl)dipyrrolidine-2-carboxamide) 
Cl3] (14): Anal. Calcd. For C16H22Cl3N4O2Sb: C, 
36.23; H, 4.18; N, 10.56. Found: C, 36.48; H, 4.07; N, 
10.87. IR (KBr, /cm−1): 2955 ( NH), 1734 ( CO), 
1383 ( CC), 1037 ( CH). LC-MS: m/z (calcd) = 
530.97 (530.49) (M+).1H NMR (300 MHz, DMSO-
d6): 10.10 (1H, NH), 9.00 (1H, NH), 7.20 (2H, -H), 
7.00 (1H, H), 6.85 (1H, H),4.40 (1H, H), 3.70 (2H, H), 
3,20 (2H, H), 2,30 (2H, NH), 1,90 (2H, H). 13C NMR 
(100 MHz, DMSO-d6): δ 170.76, 169.59, 150.22, 
149.83, 139.23, 132.88, 130.57, 124.61, 59.10, 53.48, 
45.76, 28.37, 23.51, m.p. ˃ 400 °C, yield: 68%. 
 
In vitro leishmanial activity assay 
The method described by Östan et al. was used for 
determination of antileishmanial activity of the 
compounds.38 Promastigotes of Leishmania tropica 




were isolated from a patient from Aydın, Turkey 
using NNN medium. Promastigotes transferred to 
RPMI 1640 medium supplemented with 15% Fetal 
calf serum for mass cultivation. Compounds were 
diluted with DMSO transferred to the culture plates to 
obtain final concentrations of 250, 125, 62.5, 31.2, 
15.6, 7.8 μg/mL. After 1 h at 37 °C, 150 μL of culture 
medium complemented with 1×106 parasites/mL, 
from a logarithmic phase culture, were added. DMSO 
and Glucantime were used as drug carrier control and 
positive control (20 μg/mL), respectively. All plates 
were incubated at 26 °C. After 24, 48 and 72 h; viable 
L. tropica promastigotes were identified and counted 
microscopically with a hemocytometer on the basis of 
their aspect and motility. After incubation samples of 
each well were subcultured in fresh medium for 
another 48 h without drugs. All tests were carried out 
in triplicate. All microscopic examinations were 
performed blindly by two investigators. MLC (The 
minimum lethal concentration) was determined to be 
the lowest concentration of drugs at which no motile 
cells were found. Growth inhibition (GI) % as 
calculated with respect to the growth control is as 
follows: %GI = (1- GR extract/GRcontrol) X 100. 
 
Computational details 
Quantum calculations were carried out using the 
B3LYP/ LANL2DZ (method/basis) by Gaussian 03W 
program.36 All the structures were fully optimized. 
The absence of imaginary frequencies verified that all 
structures were true minima. The output files from 
Gaussian were transferred to the program CODESSA 
to calculate approximately 350 molecular descriptors 
(constitutional, topological, geometrical, electrostatic, 
quantum-chemical). For regression analysis, anti-
leishmanial activity values were converted to negative 
logarithm scale (pIC50 = - logIC50) and used as 
dependent variables. Calculated descriptor values 
were used as independent variables. Best Multiple 
Linear Regression method in CODESSA software 
was used to select of the descriptors, and to build the 
model equation. The “breaking point” rule was 
applied to determine the optimal number of 
descriptors in the model equations. This rule is based 
on the significant improvement of R2 (R2 < 0.02–
0.04) with respect to the number of descriptors in the 
model. Consequently, two descriptors were used as 
independent variables in our models. The squared 
correlation coefficient (R2), leave-one-out cross-
validated squared correlation coefficient (R2cv), the 
Fisher criteria (F), and standard error (s2) were used as 
criteria for the stability and the robustness of the 
models. The obtained model was also validated with 
an internal validation method.  
 
Results and Discussion 
 
Structure of the complexes 
Antimony(III) complexes given in Fig. 1, reported 
our previous studies,35-37were characterized using 
elemental analyses, LC-MS, FTIR, 1H NMR 
spectroscopy and molar conductivity measurements. 
Their geometries optimized using DFT/B3LYP/ 
LANL2DZ level in gas phase were given in Fig. 2. It 
was found that all these complexes have square-
pyramidal geometry.  
 
In vitro anti-leishmanial activity 
All complexes were tested in vitro for their 
antileishmanial activitiy againstLeishmania tropica 
promastigotes with one reference drug, Glucantime 
(20 μg/mL), and the resultswere pictorized at  
Fig. 3. In general, all complexes showed weaker 
activity compared to reference drug Glucantime  
(2.76% growth inhibition at 20 μg/mL). Sb(2-
guanidinobenzimidazole)Cl3 (6) exhibited the best 
anti-leismanial activity with 3.16% growth inhibition 
at 31.25 μg/mL. Following this, complex 5 has second 
highest anti-leishmanial activity with 7.24 % growth 
inhibition at 31.25 μg/mL, and complex 3 has the 
third highest anti-leishmanial activity with 3.42 % 
growth inhibition at 62.50 μg/mL. Generally, 
carboxamide Sb(III) complexes (9-14) showed 
moderate antileishmanial activity, and they have 
lower activity than pyrimidine-Sb(III) complexes (3, 
4, 7, 8). Among the carboxamide complexes, Sb(N-2-
pyrimidine,5-chloro-2-thiophenecarboxamide)2Cl3 
(12) has the highest anti-leishmanial activity, and 
carboxamide complex bearing pyroline group (9) has 
more activity than that of bearing piperidine group 
(10). In addition, pyrimidine-Sb(III) complexes have 
more antileishmanial activity than pyridine-Sb(III) 
complexes, and electron-donating substituents 
decrease the activity. 
 
QSAR analysis 
We also performed a QSAR (quantitative structure 
activity relationship) analysis to find the common 
parameters correlating with antileishmanial activities 
of fourteen complexes. For this reason, LC50 values 
were determined by linear regression, relating  
the inhibition percentage. Obtaining molar 
antileishmanial activity values were converted to 




negative logarithm scale (pLC50 = -logLC50) and  
used as dependent variables in regression analysis 
(Table 1). The most stable structure of all complexes 
calculated using DFT/B3LYP/LanL2DZ method was 
used to obtain average 370 descriptors with 
CODESSA (version 2.7.10) software.40 BMLR (Best 
Multi Linear Regression) method embedded in 
CODESSA software was used for multilinear 
regression analysis. 
Two-parameter equation calculated with BMLR 
method for 14 complexes is given in Table 1. In this 
table, X and ΔX are regression coefficients of the 
model equation and their standard errors, respectively. 
In this equation, r2 is a measure of the fit of the 
 
 
Fig. 1 — Structures of the synthesized antimony(III) complexes 




regression equation. s2 is the standard deviation of the 
regression. Fisher test (F) corresponds to the ratio of 
the variance of the equation and the variance due to 
the error in the equation. Higher values of the F-test 
indicate the significance of the equation. r2CV is 
“leave-one-out” (LOO) cross-validated coefficient; it 
is a practical method for testing the predictive 
performance and stability of the regression equation. 
In the model equation, the first descriptor is the 
“minimum net atomic charge for a C atom” (or the 
maximum negative atomic charge) obtained from the 
Mulliken charge distribution scheme of quantum 
chemical calculations.41,42 It is related with 
electrostatic and Coulombic interactions. The positive 
regression coefficient of this descriptor indicates that 
their higher values is favorable for the antileishmanial 
activity of the compounds. Second descriptor is 
“maximum bond order of a Cl atom”. This is a 
valency-related descriptor describing the strength of 
intramolecular bonding or multipole interactions of Cl 
atom.43 It is inversely proportional to antileishmanial 
activity due to the negative signs of regression 
coefficient.  
A graphical presentation of the relationship 
between the experimental and the predicted pLC50 
values of the equation is given in Fig. 4. Observed 
and predicted pLC50 values, their difference  
and molecular parameters in the equation is  
 
 
Fig. 2 — Ground state optimized structures of the complexes (1-14) calculated with B3LYP/LANL2DZ method 
 




listed in Table 2. Correlation matrix of the descriptors 
involved in the equation is shown in Table 3.  
No significant correlation was found between two 
descriptors (-0.0045).  
In addition to LOO method, we also used “internal 
validation” method given in Table 4. In this method, 
firstly, 14 compounds were categorized in rising order 
according to the pLC50 value, secondly, they were 
divided into three subsets A, B and C: the first, fourth, 
seventh structure, etc., formed subset (A); the second, 
fifth, eight, etc. formed subset (B); and the thirdly, 
sixth, ninth structure, etc. formed subset (C). Thirdly, 
three sets were prepared as the combination of two 
training subsets (A + B), (A + C) and (B + C). The 
remaining subsets (C, B and A, respectively) become 
the corresponding test sets. As seen in Table 4, R2 
 
 
Fig. 3 — İn vitro antileishmanial activitiy of the complexes 
Table 1 — DFT-based two parameters QSAR model equation by BMLR method 
 X X t-test Descriptor 
0 −1.5589 0.84300 −1.0659 Intercept 
1 2.1132 0.33822 3.6944 Min net atomic charge for a C atom 
2 −1.6275 0.32459 −2.4448 Max bond order of a Cl atom 
n=14 R2=0.9315 F=21.76 s2=0.014 R2cv= 0.9315 
 
Table 2 — The inhibitor activity and molecular parameters of the complexes 
Compounds No. 
Antileishmanial activity  Descriptors 
LC50 (M) pLC50 (calc) pLC50 (exp) Δcalc-exp  D1* D2** 
1 2.19x10-5 4,7890 4.660 0,1290  −0.2897 0.7350 
2 1.40x10-4 3,9121 3.854 0,0581  −0.6477 0.7292 
3 1.47x10-5 4,7509 4.833 −0,0821  −0.3214 0.7377 
4 7.38x10-5 4,2187 4.132 0,0867  −0.4284 0.7165 
5 9.63x10-5 3,9679 4.016 −0,0481  −0.5089 0.7055 
6 1.26x10-5 4,8485 4.900 −0,0515  −0.2447 0.5959 
7 2.28x10-5 4,6336 4.642 −0,0084  −0.3832 0.6698 
8 8.24x10-5 4,2069 4.084 0,1229  −0.3524 0.7928 
9 3.50x10-5 4.3358 4.456 −0,1202  −0.4313 0.7243 
10 1.71x10-4 3,8129 3.767 0,0459  −0.4331 0.6976 
11 4.08x10-5 4,3440 4.389 −0,0450  −0.4276 0.7772 
12 8.39x10-5 4,0182 4.076 −0,0578  −0.2938 1.0550 
13 3.72x10-5 4,3636 4.429 −0,0654  −0.4405 0.6309 
14 3.60x10-5 4,4799 4.444 0,0359  −0.4263 0.7184 
D1: minimum net atomic charge for a C atom 
D2: maximum bond order of a Cl atom 
 
Table 3 — Internal validation of the QSAR model 
Training Set N R2 R2cv F s2 Test Set N R2 
A+B 10 0.9733 0.9475 255.17 0.0068 C 4 0.9791 
A+C 9 0.9825 0.9524 283.14 0.0079 B 5 0.9632 




Fig. 4 — Correlation of observed and estimated pIC50 




values training set and predicting set demonstrate that 
the obtained equation has a satisfactory statistical 
stability and validity. 
 
Conclusions 
New fourteen antimony(III) complexes of  
general formula [SbLnCl3] have been synthesized  
and their anti-leishmanial activities have been 
assessed in vitro against Leishmania tropica 
promastigotes. The best complex, Sb(2-
guanidinobenzimidazole)Cl3 isdemostrated 3.16% 
growth inhibition ata concentration of 31.25 μg/mL. 
All complexes have been optimized with 
DFT/B3LYP/LANL2DZ method in the gas phase. 
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